Abstract Number: 1674 • ACR Convergence 2020
Pediatric and Adolescent One Year Protocol Kidney Biopsies Should Be Performed, Even in Patients with Complete Remission of Their Lupus Nephritis
Background/Purpose: The value of one-year protocol kidney biopsies in children who have proliferative lupus nephritis (LN) is unclear, particularly in patients who meet CARRA criteria…Abstract Number: 1675 • ACR Convergence 2020
Microstructural Damage Is Associated with Age at Disease-onset and Cognitive Impairment in Systemic Lupus Erythematosus
Background/Purpose: To compare corpus callosum (CC) volume and diffusion tensor imaging in systemic lupus erythematosus according to age of disease-onset. Methods: We selected 75 patients with…Abstract Number: 1676 • ACR Convergence 2020
Neuropsychiatric Involvement in Juvenile-onset Systemic Lupus Erythematosus (JSLE): Data from the UK JSLE Cohort Study
Background/Purpose: Juvenile-onset systemic lupus erythematosus (JSLE) is a rare autoimmune/inflammatory disease, accounting for up to 20% of SLE cases. Though clinically similar to adult-onset disease,…Abstract Number: 1677 • ACR Convergence 2020
Schizophrenia Genetics and Neuropsychiatric Features in Childhood-Onset Systemic Lupus Erythematosus
Background/Purpose: Prior studies indicate that schizophrenia and systemic lupus erythematosus (SLE) share genetic risk loci. Despite overlapping phenotypic features such as psychosis, little is known…Abstract Number: 1678 • ACR Convergence 2020
Hydroxychloroquine Blood Levels Predicts 6-Months Disease Activity in Juvenile Lupus Nephritis
Background/Purpose: Renal involvement is reported in up to 80% of juvenile systemic lupus erithematosus (JSLE) and its among the most severe manifestations in these population. Antimalarials are one of…Abstract Number: 1679 • ACR Convergence 2020
Developing a Standardized Corticosteroid Dosing Regimen in Pediatric Proliferative Lupus Nephritis
Background/Purpose: Corticosteroids (CS) remain the mainstay of therapy for childhood-onset systemic lupus erythematosus (cSLE). However, widely accepted strategies for oral (PO) or intravenous (IV) CS…Abstract Number: 1680 • ACR Convergence 2020
Lupus Anticoagulant as a Predictor of Adverse Outcomes in Children with Venous Thromboembolism
Background/Purpose: The presence of antiphospholipid antibodies, including lupus anticoagulant (LA), is a risk factor for development of venous thromboembolism (VTE) in children. The impact of…Abstract Number: 1681 • ACR Convergence 2020
Hemophagocytic Lymphohistiocytosis (HLH) Gene Variants in Childhood-onset SLE (cSLE) with Macrophage Activation Syndrome (MAS)
Background/Purpose: Familial Hemophagocytic lymphohistiocytosis (fHLH) is an autosomal recessive, hyper-inflammatory, life-threatening disease. Macrophage activation syndrome (MAS) is also known as secondary HLH due to the…Abstract Number: 1682 • ACR Convergence 2020
Goal-Setting Improves Transition Readiness in Adolescents with Juvenile Idiopathic Arthritis and Systemic Lupus Erythematosus
Background/Purpose: The transition from pediatric to adult rheumatology care is associated with increased morbidity, mortality and loss to follow-up. This is largely due to a…Abstract Number: 1683 • ACR Convergence 2020
Ready or Not? Measuring Readiness for Transition to Adult Care in Adolescents with JIA & jSLE
Background/Purpose: Transitioning from pediatric to adult care represents a particularly vulnerable period among patients with JIA and jSLE. The shift to adult care is often…Abstract Number: 1684 • ACR Convergence 2020
Increase in Emergency Department Visits and Hospitalizations, Decrease in Outpatient Visits Following Transition to Adult Rheumatologic Care
Background/Purpose: Many children with rheumatic disease have active disease as adults, and health care gaps often occur in the transition from pediatric to adult care.…Abstract Number: 1685 • ACR Convergence 2020
Impact of the COVID-19 Pandemic Among Children with Rheumatic Diseases from Around the Globe
Background/Purpose: Children with rheumatic diseases face unknown risks in the setting of the COVID-19 pandemic. These children are often immunosuppressed due to their underlying disease…Abstract Number: 1686 • ACR Convergence 2020
The COV-ASAKI Survey from the Pediatric Tuscany Network During COVID-19 Era
Background/Purpose: At the end of April 2020, national and international Pediatrics scientific societies diffused an alert about a rise in the number of pediatric severe,…Abstract Number: 1687 • ACR Convergence 2020
Kawasaki Disease Shock Syndrome in the Intensive Care Unit: A Single Center Cohort
Background/Purpose: Kawasaki disease (KD), a well described vasculitis of childhood, is the leading cause of acquired heart disease in developed countries. Kawasaki disease shock syndrome…Abstract Number: 1688 • ACR Convergence 2020
Long-term Hearing Loss, Anxiety and Neurodevelopmental Outcomes Following Kawasaki Disease: A Population-based Cohort Study
Background/Purpose: The incidence of Kawasaki disease (KD) is increasing in Ontario. Cardiovascular sequelae following KD are well-described. However, there are limited and conflicting non-cardiovascular outcome…
- « Previous Page
- 1
- …
- 946
- 947
- 948
- 949
- 950
- …
- 2607
- Next Page »
